sodium thiosulfate formulation DB-020

An injectable sterile viscous solution composed of the thiol-containing reducing agent sodium thiosulfate (STS) pentahydrate formulated in sodium hyaluronate in sterile water that can be used to prevent ototoxicity. Upon administration into the ear via trans tympanic injection, thiosulfate targets and irreversibly binds to cisplatin. This inactivates cisplatin locally in the cochlea and prevents hearing loss caused by cisplatin without interfering with cisplatin’s anti-cancer activity. As DB-020 can be administered directly to the ear prior to each cycle of chemotherapy, it may protect the ear from cisplatin’s ototoxic effects.